Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Top Cited Papers
Open Access
- 18 October 2025
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 157 (1) , 143-154
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Novartis Pharmaceuticals Corporation
This publication has 28 references indexed in Scilit:
- Chronic Spontaneous UrticariaJAMA, 2024
- A Practical Approach to Diagnosing and Managing Chronic Spontaneous UrticariaDermatology and Therapy, 2024
- THE URTICARIA VOICES STUDY: ANTIHISTAMINE TREATMENT PATTERNS AND PATIENT REPORTED CONTROL IN CHRONIC SPONTANEOUS URTICARIAAnnals of Allergy, Asthma & Immunology, 2023
- Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical responseClinical and Translational Allergy, 2023
- Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature ReviewDermatology and Therapy, 2021
- Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune DiseaseDrugs, 2021
- Patients with Chronic Urticaria Remain Largely Undertreated: Results from the DERMLINE Online SurveyDermatology and Therapy, 2021
- Current and emerging treatments for chronic spontaneous urticariaAnnals of Allergy, Asthma & Immunology, 2020
- Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World EvidenceClinical Reviews in Allergy & Immunology, 2020
- Chronic urticaria—new concepts regarding pathogenesis and treatmentCurrent Allergy and Asthma Reports, 2002